131 related articles for article (PubMed ID: 36162540)
1. Post treatment with Gastrodin suppresses oxidative stress and attenuates motor disorders following 6-OHDA induced Parkinson disease.
Sadeghian Z; Eyvari-Brooshghalan S; Sabahi M; Nourouzi N; Haddadi R
Neurosci Lett; 2022 Nov; 790():136884. PubMed ID: 36162540
[TBL] [Abstract][Full Text] [Related]
2. Gastrodin microinjection suppresses 6-OHDA-induced motor impairments in parkinsonian rats: insights into oxidative balance and microglial activation in SNc.
Haddadi R; Poursina M; Zeraati F; Nadi F
Inflammopharmacology; 2018 Oct; 26(5):1305-1316. PubMed ID: 29616453
[TBL] [Abstract][Full Text] [Related]
3. Silibinin chronic treatment in a rat model of Parkinson disease: A comprehensive in-vivo evaluation and in silico molecular modeling.
Eyvari Brooshghalan S; Sabahi M; Ebadi SA; Sadeghian Z; Mohajjel Nayebi A; Haddadi R
Eur J Pharmacol; 2023 Feb; 941():175517. PubMed ID: 36669615
[TBL] [Abstract][Full Text] [Related]
4. Silymarin prevents apoptosis through inhibiting the Bax/caspase-3 expression and suppresses toll like receptor-4 pathway in the SNc of 6-OHDA intoxicated rats.
Haddadi R; Nayebi AM; Eyvari Brooshghalan S
Biomed Pharmacother; 2018 Aug; 104():127-136. PubMed ID: 29772432
[TBL] [Abstract][Full Text] [Related]
5. Effects of WR1065 on 6-hydroxydopamine-induced motor imbalance: Possible involvement of oxidative stress and inflammatory cytokines.
Kheradmand A; Nayebi AM; Jorjani M; Khalifeh S; Haddadi R
Neurosci Lett; 2016 Aug; 627():7-12. PubMed ID: 27222379
[TBL] [Abstract][Full Text] [Related]
6. Protective effects of Althaea officinalis L. extract in 6-hydroxydopamine-induced hemi-Parkinsonism model: behavioral, biochemical and histochemical evidence.
Rezaei M; Alirezaei M
J Physiol Sci; 2014 May; 64(3):171-6. PubMed ID: 24464760
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease.
Khan MM; Ahmad A; Ishrat T; Khan MB; Hoda MN; Khuwaja G; Raza SS; Khan A; Javed H; Vaibhav K; Islam F
Brain Res; 2010 Apr; 1328():139-51. PubMed ID: 20167206
[TBL] [Abstract][Full Text] [Related]
8. Short-Term Treatment with Silymarin Improved 6-OHDA-Induced Catalepsy and Motor Imbalance in Hemi-Parkisonian Rats.
Haddadi R; Eyvari Brooshghalan S; Farajniya S; Mohajjel Nayebi A; Sharifi H
Adv Pharm Bull; 2015 Nov; 5(4):463-9. PubMed ID: 26819917
[TBL] [Abstract][Full Text] [Related]
9. Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-OHDA hemi-parkinsonian rats.
Haddadi R; Mohajjel Nayebi A; Brooshghalan SE
Neurosci Lett; 2013 Oct; 555():106-11. PubMed ID: 24045063
[TBL] [Abstract][Full Text] [Related]
10. Neuronal degeneration and oxidative stress in the SNc of 6-OHDA intoxicated rats; improving role of silymarin long-term treatment.
Haddadi R; Eyvari-Brooshghalan S; Nayebi AM; Sabahi M; Ahmadi SA
Naunyn Schmiedebergs Arch Pharmacol; 2020 Dec; 393(12):2427-2437. PubMed ID: 32715318
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Effects of Selenium on Alpha-Synuclein Accumulation in Substantia Nigra Pars Compacta in a Rat Model of Parkinson's Disease: Behavioral and Biochemical Outcomes.
Salaramoli S; Joshaghani HR; Hosseini M; Hashemy SI
Biol Trace Elem Res; 2024 Mar; 202(3):1115-1125. PubMed ID: 37386228
[TBL] [Abstract][Full Text] [Related]
12. Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway.
Christensen AB; Sørensen JCH; Ettrup KS; Orlowski D; Bjarkam CR
Brain Res Bull; 2018 May; 139():167-173. PubMed ID: 29462643
[TBL] [Abstract][Full Text] [Related]
13. Rutin protects dopaminergic neurons from oxidative stress in an animal model of Parkinson's disease.
Khan MM; Raza SS; Javed H; Ahmad A; Khan A; Islam F; Safhi MM; Islam F
Neurotox Res; 2012 Jul; 22(1):1-15. PubMed ID: 22194158
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular evaluation of female rats with 6-OHDA-induced parkinsonism: Possible protection by ovarian hormones and participation of nitric oxide.
de Campos BH; de Jager L; Reginato GS; Pereira RS; Crestani CC; Pinge-Filho P; Martins-Pinge MC
Life Sci; 2020 Oct; 259():118259. PubMed ID: 32795538
[TBL] [Abstract][Full Text] [Related]
15. Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats.
Mahmoudi J; Nayebi AM; Samini M; Reyhani-Rad S; Babapour V
Pharmacol Rep; 2011; 63(4):908-14. PubMed ID: 22001978
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies.
Sarukhani M; Haghdoost-Yazdi H; Sarbazi Golezari A; Babayan-Tazehkand A; Dargahi T; Rastgoo N
Neurol Res; 2018 Jul; 40(7):523-531. PubMed ID: 29726751
[TBL] [Abstract][Full Text] [Related]
17. The effects of pergolide on memory and oxidative stress in a rat model of Parkinson's disease.
Ciobica A; Olteanu Z; Padurariu M; Hritcu L
J Physiol Biochem; 2012 Mar; 68(1):59-69. PubMed ID: 22006204
[TBL] [Abstract][Full Text] [Related]
18. A promising therapeutic potential of cerebrolysin in 6-OHDA rat model of Parkinson's disease.
Noor NA; Mohammed HS; Mourad IM; Khadrawy YA; Aboul Ezz HS
Life Sci; 2016 Jun; 155():174-9. PubMed ID: 27210889
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease.
Yildirim FB; Ozsoy O; Tanriover G; Kaya Y; Ogut E; Gemici B; Dilmac S; Ozkan A; Agar A; Aslan M
Neurochem Int; 2014 Dec; 79():1-11. PubMed ID: 25263280
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T
Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
